The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant IL-2 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of autoimmune diseases and immune-mediated inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.本發明概言之係關於免疫球蛋白及介白素-2(IL-2)之融合蛋白。更特定而言，本發明係關於免疫球蛋白及突變體IL-2之融合蛋白，其展現用作(例如)治療自體免疫疾病及免疫介導之發炎性疾病之治療劑之改良性質。此外，本發明係關於編碼該等融合蛋白之多核苷酸及包括該等多核苷酸之載體及宿主細胞。本發明另外係關於產生本發明之該等融合蛋白之方法及使用其治療疾病之方法。
